# Biomatter

> Vilnius biotech enterprise designing custom enzymes with generative models and laboratory testing.

## Why it is interesting

$18M November 2026 Series A led by Astanor after a separate €6.5M seed in 2024. Company reports 25+ customer companies, 50+ delivered enzymes and a production reagent case; these are issuer statements, not audited revenue.

## Profile

- **Latest funding:** Series A — $18M new funding (November 12, 2026)
- **Latest known valuation:** Not publicly disclosed
- **Total disclosed equity funding:** $18M
- **Stage:** series-a
- **Status:** private
- **Industries:** N/A
- **Coverage:** full
- **Last updated:** 2026-11-13
- **Latest funding investors:** Astanor, UVC Partners, Inventure, Metaplanet

## Key facts

- Nov 12 2026 $18M Series A led by Astanor.
- Aug 5 2024 distinct €6.5M seed co-led UVC and Inventure.
- Issuer says 25+ enterprise clients and 50+ custom enzymes delivered; proposed 2027 Vilnius lab.

## Funding history

- Series A · $18M new funding · November 12, 2026
  Source: https://www.businesswire.com/news/home/20261111065246/en/
- Seed · €6.5M new funding · August 5, 2024
  Source: https://www.unternehmertum.de/presse/biomatter-erhaelt-6-5-millionen-euro-fuer-die-entwicklung-neuartiger-enzyme-mit-seiner-generativen-ki-plattform/

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)
**Last updated:** November 13, 2026

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.

---
Source: https://venturecapitaltracker.com/startup/biomatter